Study Design
This is a prospective non-randomized preliminary study for observing the effectiveness and safety of using intralesional methylprednisolone to treat patients in the active phase of Peyronie’s disease. Patients who applied to our clinic for Peyronie’s disease and who were in the active phase of the disease between 2018 and 2020 were included in the study. To confirm that the disease was in the acute phase, we used the following criteria for inclusion: (1) less than 12 months passed since the onset of complaints; (2) absence of calcified plaque in penile duplex doppler ultrasound; (3) symptoms of painful erection; and (4) recent change in penile curvature. Patients who had completed the acute phase and progressed to the chronic phase disease stage, who had the presence of calcified plaque, who had prior medical or surgical treatment for Peyronie’s disease, who had a history of extra corporeal shock wave therapy (ESWT), who had hourglass and hinge deformity, and who were not sexually active were excluded from the study. Apart from hourglass and hinge deformity, patients with all types of curvature were included in the study.